In early 2023, Sanofi Ventures received a commitment from its parent company for an additional multi-year commitment. The capital will be increased to more than 750 million dollar for the "evergreen venture fund." This venture capital fund focuses on early-stage investments, co-creating companies and leading financing rounds. The venture capital firm seeks to further expand its investments by focusing on companies that are driving innovation.
In addition to serving as a financial partner for early to mid-stage pharmaceutical companies, the Evergreen Venture Fund will support future business development efforts and merger and acquisition opportunities within Sanofi. The additional investment amount, confirmed by the Board of Directors, will also support the expansion and investment capacity of the Sanofi Ventures team on a global scale. Commenting on the move, Paul Hudson, Chief Executive Officer of Sanofi, said, “Sanofi’s purpose in chasing the miracles of science reaches far beyond our labs. As we continue to build our best-in-class pipeline, we are investing in early stage companies that share our ambition of delivering transformative science and digital innovation. This capital commitment signals Sanofi’s accelerated ambitions in the venture capital community and our continued desire to collaborate with global innovators in the best interests of patients.”
Jason P. Hafler, executive director at Sanofi Ventures, added, “We are grateful for Sanofi’s support over the past decade and appreciate their renewed commitment to early stage innovations that will fuel the next generation of transformative companies aiming to improve the lives of patients.”
In 2022, Sanofi Ventures completed ten investments in global therapeutic and digital areas of strategic interest to Sanofi. Since inception, 80 percent of investments have been in biotherapeutics and 20 percent in digital health companies. The firm invests in top innovators working in areas such as immunology and inflammation, rare diseases, oncology, cell and gene therapy, vaccines, and digital health and data science. The venture capital firm partners with private companies at all stages of their lifecycle, from seed to Series B stage and beyond, executing financings, serving on boards, and working with biotech and digital health companies to create long-term value through future financings and IPOs.
